On March 28, 2024, Bristol-Myers Squibb Company has filed a definitive proxy statement soliciting proxies and urged the shareholders to vote against the shareholder proposal from Kenneth Steiner, requesting the Company board of directors to adopt an enduring policy, and amend the governing documents as necessary in order that 2 separate people hold the office of the Chairman and the office of the CEO at its annual general meeting of shareholders scheduled to be held on May 7, 2024.